Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia

Pediatric Infectious Disease Journal

Volumn 29, Issue 7, 2010, Pages 607-612

  Jardine, Andrew ^a,b   Menzies, Robert I ^a   McIntyre, Peter B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b The Australian National University   (Australia)

Author keywords

heptavalent pneumococcal conjugate vaccine; hospitalization; immunization schedule; pneumonia

Indexed keywords

PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CHILD; DATA BASE; DISEASE ASSOCIATION; FEMALE; FUNDING; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD; VACCINATION; ADOLESCENT; IMMUNOLOGY; INFANT; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; PROCEDURES; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AUSTRALIA; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; VACCINATION; YOUNG ADULT;

EID: 77954336895     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181d7d09c     Document Type: Article

References (44)

1. Burgner D, Richmond P. The burden of pneumonia in children: an Australian perspective. Paediatr Respir Rev. 2005;6:94-100.
2. Skull SA, Andrews RM, Byrnes GB, et al. Hospitalized community-acquired pneumonia in the elderly: an Australian case-cohort study. Epidemiol Infect. 2009;137:194-202.
3. Farha T, Thomson AH. The burden of pneumonia in children in the developed world. Paediatr Respir Rev. 2005;6:76-82.
4. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103:309-316.
5. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642-1650.
6. Wardlaw T, Johansson EW, Hodge M. Pneumonia: the forgotten killer of children. The United Nations Childrens Fund (UNICEF)/World Health Organisation (WHO), 2006. Available at: http://www.unicef.org/publications/files/Pneumonia- The-Forgotten-Killer-of-Children.pdf. Accessed March 18, 2009.
7. Juven T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19:293-298.
8. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113:701-707.
9. Cevey-Macherel M, Galetto-Lacour A, Gervaix A, et al. Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. Eur J Pediatr. 2009;168:1429-1436.
10. Lim I, Shaw DR, Stanley DP, et al. A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust. 1989;151:87-91.
11. Charles PG, Whitby M, Fuller AJ, et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis. 2008;46:1513-1521.
12. National Health and Medical Research Council. The Australian Immunisation Handbook. Canberra, Australia: Australian Government Department of Health and Aging; 2008.
13. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-815.
14. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumo-coccal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348.
15. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumo-coccal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139-1146. (Pubitemid 40417563)
16. Mahon BE, Hsu K, Karumuri S, et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine. 2006;24:2514-2520.
17. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
18. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
19. Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med. 2007;161:1162-1168.
20. Grijalva CG, Griffin MR, Nuorti JP, et al. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine\United States, 1997-2006. MMWR Morb Mortal Wkly Rep. 2009; 58:1-4.
21. Nelson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26:4947-4954.
22. De Wals P, Robin E, Fortin E, et al. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J. 2008;27:963-968
23. National Centre for Classification in Health. International Classification of Diseases, 10th revision, Australian Modification (ICD-10-AM). 2nd ed. Sydney, Australia: National Centre for Classification in Health; 2000.
24. Marrie TJ. Pneumococcal pneumonia: epidemiology and clinical features. Semin Respir Infect. 1999;14:227-236.
25. Elliott JH, Anstey NM, Jacups SP, et al. Community-acquired pneumonia in northern Australia: low mortality in a tropical region using locally-developed treatment guidelines. Int J Infect Dis. 2005;9:15-20.
26. Thompson JE. Community acquired pneumonia in north eastern Australia\a hospital based study of Aboriginal and non-Aboriginal patients. Intern Med J. 1997;27:59-61.
27. Australian Institute of Health and Welfare. Improving the quality of indigenous identification in hospital separations data. AIHW cat. no. HSE 101 (Health Services Series no. 25). Canberra, Australia: AIHW; 2005.
28. Brotherton J, Wang H, Schaffer A, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2003 to 2005. Commun Dis Intell. 2007;31(suppl):S1-S152.
29. Lopalco P, Editorial team. Use of 7-valent pneumococcal conjugate vaccine in EU. Euro Surveill. 2006;11: 3092. Available at: http://www.eurosurveillance. org/ViewArticle.aspx?ArticleId=3092. Accessed June 19, 2008.
30. Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents\United States 2007. Pediatrics. 2007; 119, 207-208.
31. Millar EV, O'Brien KL, Bronsdon MA, et al. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44:1173-1179.
32. Dagan R, Givon-Lavi N, Fraser D, et al. Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopha-ryngeal acquisition of pneumococcus. J Infect Dis. 2005;192:367-376.
33. Jardine A, Menzies RI, Deeks SL, et al. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J. 2009;28:761-765.
34. Menzies R, Turnour C, Chiu C, et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006. Commun Dis Intell. 2008;32(suppl):S2-S67.
35. Boulianne N, De Wals P, Deceuninck G, et al. Impact du programme d?immunisation par le vaccine pneumococcique conjugue heptavelent (VPC-7), au Quebec, Canada. Institut National de Sante Publique de Quebec, 2007. Available at: http://www.inspq.qc.ca/publications/notice.asp? E=p&NumPublication=681. Accessed May 20, 2009.
36. Darling N, Kolasa M, Wooten KG. National, state, and local area vaccination coverage among children aged 19-35 months\United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57:961-966.
37. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336: 243-250.
38. Lee RW, Lindstrom ST. A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia. Respirology. 2007;12:754-758.
39. Maxwell DJ, McIntosh KA, Pulver LK, et al. Empiric management of community-acquired pneumonia in Australian emergency departments. Med J Aust. 2005;183:520-524.
40. Isaacs D. Problems in determining the etiology of community-acquired childhood pneumonia. Pediatr Infect Dis J. 1989;8:143-148.
41. Skull SA, Andrews RM, Byrnes GB, et al. ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged ≥65 years. Epidemiol Infect. 2008;136:232-240.
42. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization\WHO position paper. Wkly Epidemiol Rec. 2007;82:93-104.
43. Sinha A, Levine O, Knoll MD, et al. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet. 2007;369:389-396.
44. Ramsay ME, McVernon J, Andrews NJ, et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis. 2003;188:481-485.